



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 16th November 2022

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GP Clinical Lead for Quality for Lancashire and South Cumbria ICS
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
Mr Chris Woods (CW)	Head of Contracting and Costing, Finance

IN ATTENDANCE:

Mr Matthew Tattersall (MT)	Clinical Pharmacist, Pharmacy ELHT
Mr Hani Hannah (HH)	Clinical Pharmacist, Pharmacy ELHT
Ms Hollie Ringrose (HR)	Consultant in Rehabilitation Medicine (ELHT)

2022/171: APOLOGIES:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr D Sebastian (DS)	Consultant Intensivist and Deputy DMD for SAS
Mr M Maher	(Consultant Gynaecology & Sexual Health)

2022/172: DECLARATION OF INTEREST

None declared - relevant to agenda items

2022/173: MINUTES OF OCTOBER TEAMS MEETING:

Accepted as accurate record.

2022/174: MATTERS ARISING:

2021/101b: ELMMB Membership – to remain on action matrix as a standing item for feedback.



2022/136g: Biotin and Alpha tocopherol supplements: The associated costs of prescribing these supplements in primary care have been more than £10,000, when the actual Over-the-counter cost is significantly lower. LR presented prescribing data: East Lancashire between 09/2021 and 08/2022: Total 70 items at a cost of £9160; Blackburn with Darwen between 09/2021 and 08/2022: Total 13 items at a cost of £4800. Most of the prescribing is considered vital to treatment and several options to secure a more centralised dispensing and procurement were discussed.

ACTION: LR to escalate to explore a more central distribution method for these and other supplements. To be closed for now.

2022/156a: Formulary Updates: Gepan Instill: requested by Mr Hill as Amber traffic light to allow prescribing to continue in primary care for 6 months after commencing treatment in secondary care. The product requires no monitoring, and the next review will be at the end of the treatment period. JV to investigate the option for prescribing to be done through the Appliance Prescription Service who would be able to monitor patients and highlight them for review.

ACTION: JV to discuss with APS team

2022/156f: Valaciclovir 500mg tablets – deferred to December meeting

2022/175 New Product Request

AEROTRACH PLUS Anti-Static Valved Holding Chamber; Requested for use with MDI inhalers in patients with a tracheostomy. The device is a spacer designed to fit on the tracheostomy tube, allowing patients to continue with inhaler treatment. It has been trialled in several patients with good outcomes. It was suggested that prescribing would be initiated within the hospital setting for new patients on discharge and it is advised that the device is replaced at 4 monthly intervals. Existing patients may need to be identified by secondary care to facilitate GPs providing a device to this cohort. JV pointed out that further information would be required from the manufacturer as the product is not currently in the Drug Tariff.

ACTION: MT to share company contact details with JV. MT to provide a list of historical patients.

2022/176 Formulary Updates

Melatonin: Currently amber shared care for patients under the age of 18 years with sleep disorders. However, when the patient reaches the age of 18 years they currently transfer across, but there is no official pathway for this cohort of patients. Ideally, they should be referred to adult services. The request is to allow prescribing [as AMBER] for paediatric patients who become adults and those above 18 years with neurodevelopmental disorders who develop sleep problems.

Concerns were raised that there could be confusion trying to differentiate between this group of patients and that further discussion is required outside of this meeting.

ACTION: Meeting to arranged to discuss further and bring back to ELMMB

Emeside 250 mg/5ml Syrup: Cost-effective brand of ethosuximide. To prescribe by brand. **Traffic Light AMBER**



Promethazine tablets and Liquid: Currently Green traffic light. Request to change to RED traffic light for anxiety and insomnia. There are a significant number of patients who have been identified as taking promethazine for this indication, which is only licensed for short-term use. A structured approach will be needed to review patients appropriately. UA to share guideline used by LSCFT that supports de-prescribing of promethazine. Agreed as RED traffic light for insomnia

Traffic Light RED

Colloidal oatmeal creams: Request to allow generic prescribing on formulary to support the ongoing shortage of Aveeno and Epimax oatmeal formulations.

Traffic Light GREEN

Slentyto 1 mg, 5mg prolonged-release tablets: for use on a named patient basis for paediatric patients unable to tolerate liquid and struggle to take circadin [crushed or swallowed whole]. The tablets are smaller, and the strengths will facilitate fewer tablets being taken. Restricted to use in paediatrics only.

Traffic Light AMBER

Lamotrigine 2mg, 5mg, 25mg and 100mg chewable/dispersible tablets and Lamotrigine 100mg tablets: currently only 25mg, 50mg tablets are on formulary. Request to include further strengths and formulations to satisfy the SmPC which advises not to attempt to administer partial quantities for the chewable/dispersible tablets. Agreed to include in formulary

Traffic Light AMBER

RESOLVED: Formulary to be updated where appropriate

2022/177 LSCMMG Consultations –November 2022 [deadline 1/12/22]

- a. Sativex for refractory neuropathic pain – circulated to chronic pain team Consultants for comments. SJ commented that NICE NG144 was published in 2019 and updated in March 2021. It says "do not offer CBD (Sativex) to manage chronic pain unless as part of a clinical trial." It seems that neuropathic pain is one type of chronic pain, and that we should abide by the latest guideline and not approve it for this purpose. AB to feedback comments and recommend black traffic light.
- b. Psoriatic Arthritis guideline – circulated to rheumatology directorate for comments
- c. Gout Prescribing Guidance – update: circulated to rheumatology directorate for comments. SJ commented that the updated document does not capture some of the changes published in latest NICE guidelines.

For Action: Comments to be sent to LSCMMG

2022/178 LSCMMG Recommendations–October 2022

- a. Use of medicines outside of their UK Marketing Authorisation in pain management – updated
- b. Generic biosimilar medicines position statement – *update to follow*
- c. Asthma treatment guideline for adults aged 17 and over – updated
- d. Atrial Fibrillation pathway – updated. It was noted that the comments feedback regarding weight issues and use of edoxaban had not been addressed in the updated document



Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2022/179 Pharmacy and Medicines Policy Task and Finish Group recommendations sheet (*formally SCC*) – October 2022

- a. Paliperidone palmitate prolonged release suspension for injection (six monthly) – Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products – **RED**
- b. Mexiletine – Treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening. – **RED**.
This is currently agreed as **AMBER traffic light** on ELMMB
- c. Testosterone gel – As supplementation for menopausal women with low sexual desire if HRT alone is not effective – **AMBER1**
- d. Vedolizumab SC – Crohn's disease & Ulcerative colitis – **RED**
- e. Infliximab SC – Crohn's disease & Ulcerative colitis – **RED**
- f. Botulinum Toxin Type A – For treatment of primary idiopathic hyperhidrosis and secondary hyperhidrosis – **RED**
- g. Liothyronine – Add-on treatment for refractory hypothyroidism despite adequate replacement with levothyroxine – new patients – **AMBER 0**:
Currently agreed and remains as **RED Traffic Light on ELMMB**
- h. Liothyronine – Add-on treatment for refractory hypothyroidism – existing patients. – **AMBER 0**:
Currently agreed and remains as **RED Traffic Light on ELMMB**
- i. Liothyronine – Liothyronine monotherapy for the management of chronic hypothyroidism – primary and secondary care – **BLACK**

RESOLVED: Website to be updated accordingly.

ACTION: JV to contact LSCMMG to explain rationale and decision for liothyronine. It was also discussed that feedback should be given to LSCMMG asking that the requestor be present at LSCMMG meetings. LR to raise at next Heads of Medicines Management meeting.

2022/180 Other Items

Expanded Access/Compassionate use schemes in Oncology: the schemes offer access pre-NICE available and pre-licensed drugs. ELHT are under extreme pressures trying to manage the schemes as they require extra facilitation to manage for individual patients. This has been raised and discussed at the Lancashire and South Cumbria Cancer Alliance and it has been noted that there no equity and some confusion as to who is offering the scheme across the footprint. The Cancer Alliance has recommended suspending the scheme and plan to rationalise where they are undertaken. ELMMB member support is required to support the Cancer alliance decision as they are not a statutory body. It was requested that the alliance provide a formal position statement that could be formalised and used by ELHT. It was agreed that a position statement would need to go to LSCMMG and be circulated to all oncologists to avoid raising patient expectations



ACTION: HH to request formal position statement from the Cancer Alliance and bring to next ELMMB.

2022/188 Other Items

End of Life Drugs: LR informed the Board that there has been a request to use Octreotide as part of the EoL drugs available through a new and revised community pharmacy Palliative Care/Specialist Drugs service specification across LS&C. This is currently RED Traffic Light and requires further discussion with a Hospice Consultant. LR to summarise in an email and bring to next meeting.

ACTION: LR to update ELMMB members at December meeting

2022/181 NICE Guidance – October 2022

NG226 Osteoarthritis in over 16s: diagnosis and management

Updated 19th October 2022

2022/182 NICE Recommendations – October 2022

Oral 5zacytidine for maintenance treatment of acute myeloid leukaemia after induction therapy as an option by Approved in line with TA827.

NHS England Commissioned

Traffic Light: RED

Ozanimod for treating moderately to severely active ulcerative colitis as an option by NICE. Approved in line with NICE TA828.

ICS Commissioned [Blueteq required]

Traffic Light: RED

Pembrolizumab for adjuvant treatment of renal cell carcinoma as an option by NICE. Approved in line with NICE TA830

NHS England Commissioned

Traffic Light: RED

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer is not recommended by NICE TA831

Traffic Light: BLACK

Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids as an option by NICE. Approved in line with NICE TA832

ICS Commissioned [Blueteq required]**

Traffic Light: AMBER

Zanubrutinib for treating Waldenstrom's macroglobulinaemia as an option by NICE. Approved in line with NICE TA833

NHS England Commissioned

Traffic Light: RED

SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) and is not recommended by NICE TA834

Traffic Light: BLACK

Fostamatinib for treating refractory chronic immune thrombocytopenia as an option by NICE. Approved in line with NICE TA835

ICS Commissioned [Blueteq required]

Traffic Light: RED



Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as an option by NICE. Approved in line with NICE TA836

NHS England Commissioned

Traffic Light: RED

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma as an option by NICE. Approved in line with NICE TA837

NHS England Commissioned

Traffic Light: RED

** SJ commented on TA832 that it should be noted that patients should be counselled to ensure that they use adequate contraception, as they must stop taking the pill, and that they are not pregnant when starting this drug. Also, they must not miss any of the medication as they could get pregnant.

Resolved: Items acknowledged by ELMMB

2022/183 NICE Highly Specialised Technologies –October 2022

None this month

2022/184 EAMS (Early access to medicines scheme) –October 2022

None this month

Resolved: Item acknowledged by ELMMB

Standing Items:

2022/185 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 13th October 2022

Resolved: Minutes acknowledged.

2022/186 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Next meeting: Thursday 24th November 2022

2022/187 For Action/Information: Antimicrobial Stewardship Committee (ASC)

None this month

DATE OF NEXT MEETING – Wednesday 14th December 2022 12.30pm via 'Microsoft Teams'
(Please note the meeting has been brought forward 1 week to avoid Christmas week)



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 16th November 2022

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that. Await full ICB structure	LR/VG	Jan 23
2022/156 a	Formulary Updates Gepan Instill JV to discuss possibility of prescribing being through Appliance Prescription Service	JV	Dec 22
2022/156f	Valaciclovir 500mg tablets Deferred to December meeting	VG	Dec 22
2022/175	AEROTRACH PLUS Anti-Static Valved Holding Chamber MT to share company contact details with JV. MT to provide a list of historical patients. JV to contact company regarding drug tariff	MT/JV	Dec 22
2022/176a	Formulary Updates Melatonin: request to prescribe as AMBER traffic light for paediatric patients who become adults and those above 18yrs with neurodevelopmental disorders who develop sleeping problems) Meeting to arranged to discuss further and bring back to ELMMB	AB	Dec 22
2022/180	Other items: Expanded Access/Compassionate use schemes in Oncology HH to request formal position statement from Cancer Alliance	HH	Dec 22
2022/188	Octreotide [for use in EoL service specification] Request to use as part of new/updated community pharmacy commissioned service. Currently RED on formulary. LR to email Hospice consultant to discuss place in service.	LR	Dec 22